{"id":50979,"date":"2025-12-16T22:13:06","date_gmt":"2025-12-16T14:13:06","guid":{"rendered":"https:\/\/flcube.com\/?p=50979"},"modified":"2025-12-16T22:13:07","modified_gmt":"2025-12-16T14:13:07","slug":"johnson-johnsons-tecvayli-gets-fda-priority-review-for-myeloma-combo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50979","title":{"rendered":"Johnson & Johnson’s TECVAYLI Gets FDA Priority Review for Myeloma Combo"},"content":{"rendered":"\n

Johnson & Johnson<\/strong> (NYSE: JNJ<\/a>) announced that the U.S. FDA selected the teclistamab MajesTEC\u20113 supplemental Biologics License Application (sBLA)<\/strong> to participate in the Commissioner\u2019s National Priority Voucher (CNPV) Pilot Program<\/strong>. The Phase\u202f3 MajesTEC\u20113 study showed TECVAYLI (teclistamab\u2011cqyv) plus DARZALEX FASPRO<\/strong> significantly improved progression\u2011free survival (PFS) and overall survival (OS)<\/strong> at three years vs. standard treatment in relapsed\/refractory multiple myeloma (RRMM)<\/strong> patients with 1\u20113 prior lines of therapy.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Program<\/strong><\/td>Commissioner\u2019s National Priority Voucher (CNPV) Pilot Program<\/td><\/tr>
Application<\/strong><\/td>Teclistamab MajesTEC\u20113 sBLA<\/td><\/tr>
Study<\/strong><\/td>Phase\u202f3 MajesTEC\u20113<\/td><\/tr>
Population<\/strong><\/td>RRMM patients with 1\u20113 prior lines of therapy<\/td><\/tr>
Primary Endpoints<\/strong><\/td>PFS and OS (3\u2011year follow\u2011up)<\/td><\/tr>
FDA Review Timeline<\/strong><\/td>1\u20112 months under CNPV (accepted Nov\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Data Summary<\/h2>\n\n\n\n
Endpoint<\/th>TECVAYLI + DARZALEX FASPRO<\/th>Standard Treatment<\/th>Statistical Significance<\/th><\/tr><\/thead>
Progression\u2011Free Survival<\/strong><\/td>Statistically significant advantage<\/td>Baseline<\/td>Superior at 3 years<\/td><\/tr>
Overall Survival<\/strong><\/td>Statistically significant advantage<\/td>Baseline<\/td>Superior at 3 years<\/td><\/tr>
Study Design<\/strong><\/td>Randomized Phase\u202f3 vs. standard therapy<\/td>\u2014<\/td>Demonstrates combo superiority<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile<\/h2>\n\n\n\n

TECVAYLI (Teclistamab\u2011cqyv)<\/h3>\n\n\n\n
Attribute<\/th>Details<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Bispecific T\u2011cell engager (CD3 \u00d7 BCMA)<\/td><\/tr>
Approval<\/strong><\/td>Accelerated approval Oct\u202f2022 for RRMM (\u22654 prior lines)<\/td><\/tr>
Administration<\/strong><\/td>Subcutaneous injection, off\u2011the\u2011shelf<\/td><\/tr>
Innovation<\/strong><\/td>First\u2011in\u2011class bispecific antibody for multiple myeloma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

DARZALEX FASPRO<\/h3>\n\n\n\n
Attribute<\/th>Details<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Subcutaneous CD38\u2011directed antibody<\/td><\/tr>
Approval<\/strong><\/td>May\u202f2020 (U.S.)<\/td><\/tr>
Indications<\/strong><\/td>11 approvals in multiple myeloma (4 frontline)<\/td><\/tr>
Advantage<\/strong><\/td>Only subcutaneous CD38 antibody approved in MM<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
Global MM Market<\/strong><\/td>$22\u202fbillion (2025)<\/td>Second\u2011line segment growing<\/td><\/tr>
RRMM Patients (1\u20113 prior lines)<\/strong><\/td>~40,000 annually (US\/EU)<\/td>High unmet need post\u2011lenalidomide<\/td><\/tr>
TECVAYLI Peak Sales<\/strong><\/td>$3\u20115\u202fbillion<\/strong> (global estimate)<\/td>If sBLA approved in earlier lines<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Competes with Carvykti, Abecma (CAR\u2011T) and Talvey (GPRC5D)<\/td>Bispecific convenience vs. cell therapy logistics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n